marked.bio

Company

Replimune

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

nivolumab 2relatlimab 1pembrolizumab 1

Trials

2 of 2 trials shown

  1. VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

    Recruiting Phase 3 Replimune Started 2024Primary completion 2030-09 NCT06264180

    Vusolimogene OderparepvecnivolumabrelatlimabpembrolizumabSingle-agent chemotherapy

    …apy must be the immediate prior line of treatment before randomization (for patients with BRAF mutation, see I 4).

    BRAF V600EAdvanced Melanoma

  2. Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

    Active, not recruiting Phase 2 Replimune Started 2017Primary completion 2028-06 NCT03767348

    RP1nivolumab FDA EU

    Subjects with MSI-H or dMMR tumors: has diagnosis of MSI-H or metatstatic dMMR tumor (according to protocol d…

    MSI-H / dMMRNon-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma